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Abstract
Although the assessment of cardiovascular risk in individual patients takes into account a range of risk factors, the
diagnosis and management of hypertension (high blood pressure) is largely determined by a single numerical value,
albeit that often several readings are taken over time. Given the critical impact of a decision to embark on lifelong
drug therapy, the importance of ensuring that a blood pressure (BP) record is both accurate and representative is
clear. However, there is good evidence that the variability of BP is such that even if measurement is of the highest
quality, it can be difficult to say with confidence whether a patient is above or below a treatment threshold. This
commentary argues that current BP measurement is inadequate to make the clinical decisions that are necessary and
that multiple readings are required to deliver an acceptable degree of accuracy for safe decision-making. This is
impractical in a doctor’s surgery, and the only realistic long-term strategy is to involve the patient in measuring his or
her own BP in their own environment. Evidence is presented that such a strategy is better able to predict risk, is cost-
effective for diagnosing hypertension, can improve BP control and is thus better able to protect individuals in the
future.
In this commentary, I explain why doctors and other healthcare professionals should increase their familiarity with
the technology, be aware of its strengths and limitations and work with patients as they become more empowered
in the management of their chronic condition, hypertension.
Introduction
Hypertension is the most important risk factor for cardio-
vascular disease in the world [1], and evidence that lower-
ing blood pressure reduces cardiovascular risk has been
substantiated by arguably the greatest body of randomised
control trial data in clinical medicine.
Given the vast amount of information relating to
hypertension in the world literature, it is interesting to
reflect on relatively how little importance has been paid
to the measurement of blood pressure itself. A cursory
glance at many of the landmark trials over the past
25 years will show that there is no consistency in the
documentation of the measurement of blood pressure,
nor how many readings are taken to establish BP levels at
a given time. Particularly surprisingly, some studies do
not even detail how blood pressure was measured.
The measurement of blood pressure with a mercury
sphygmomanometer is now more than 100 years old
and although many primary care doctors in the United
Kingdom have moved to the use of aneroid devices, it is
the mercury manometer that has been the mainstay of
clinical trials. There is no doubt that if properly main-
tained and used correctly, this device will record an
accurate measurement of blood pressure at any point in
time.
One would hope and believe that in clinical trials,
great care is taken to measure blood pressure accurately,
but outside the confines of a trial we know that terminal
digit preference whereby readings end in either ‘0’ or ‘5’
are commonplace and the impact of the relationship
between the measurer and the measured can be consid-
erable, giving rise to what has come to be called ‘white
coat hypertension’ in its most extreme form (see below).
One of the difficulties imposed on us in clinical prac-
tice is that whilst we use data from clinical trials to
inform our decisions, doctors are always considering the
management of individual patients who may well behave
quite differently from those in trials.
Variability of Blood Pressure
Many doctors may be unaware of the enormous varia-
bility of blood pressure in an individual subject. This is
such that differences in blood pressure between succes-
sive visits to a surgery or clinic might simply relate to
random variation rather than the impact of treatment. Correspondence: Paul.Padfield@luht.scot.nhs.uk
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any medium, provided the original work is properly cited.Even in the carefully controlled environment of a clini-
cal trial, where trained nurses measure blood pressure,
differences across 2 weeks can be as much as 30 mmHg
with no treatment changes (see Figure 1).
Despite the fact that we appreciate that blood pressure
conveys risk in a continuous fashion, we have developed
cut points to define hypertension in different clinical
scenarios. The most common accepted definition of
hypertension for most individuals is 140/90 mmHg. If a
patient’s blood pressure is measured at 250/180 mmHg,
then it is likely that however many times this blood
pressure is measured, it will always be high but if the
figure is much closer to the point of definition (140/90),
it is not difficult to see that the diagnosis of hyperten-
sion may not be robust.
Some years ago, our group analysed data from the pla-
cebo arm of the Medical Research Council’s first treat-
ment trial of mild hypertension (involving many
thousands of patients) and demonstrated this lack of con-
sistency [2]. If one used a diastolic BP (DBP) of 90 mmHg
to define hypertension after 3 months of observation
in that trial, then that diagnosis would be maintained
in 80% of subjects after a further 3 months of observa-
tion. Conversely, if after 3 months DBP was < 90 mmHg
(i.e., normal), 30% could be hypertensive 3 months later.
In routine clinical practice, patients labelled as hyperten-
sive after several measurements are likely to be started
on treatment and any drop in blood pressure thereafter
attributed to the effects of the drug. While such observa-
tions may have little impact on the outcome of a clinical
trial, they will have considerable impact on how we man-
age individual patients.
It has recently been stated that the variability of blood
pressure itself may be important in determining out-
come [3], but conventional management still depends
on the assumption that the blood pressure measured
gives a fair representation of an individual’s ‘usual’ BP. It
should be clear from the above that this view is difficult
to sustain, and to be certain of an individual’s true usual
BP one would need to obtain multiple measurements to
increase confidence in categorising someone’sB Pa s
normal or not [4].
It is difficult to believe that this is practicable, given
the way health care is currently delivered, and we need
to consider alternatives if we require many measure-
ments of BP.
Out-of-Office Blood Pressure
The development of microelectronics first necessitated
by the NASA space programme has resulted in new
technologies for measuring blood pressure. Assessment
of the waveform produced by blood flowing through
arteries can be made oscillometrically, and devices now
exist which can convert such waveforms into a single
measurement of blood pressure equivalent to that
obtained using a stethoscope listening to Korotkov
sounds. This has led to two similar but different ways of
obtaining multiple blood pressure measurements.
Ambulatory Blood Pressure Monitoring
While beyond the scope of this commentary, the use of
devices that can be worn by patients over (usually) a
24-hour period with multiple measurements has demon-
strated a number of points:
Figure 1 Variability of systolic blood pressure (BP) on repeated measurement (research study conditions) taken from [16] with
permission (Padfield PL: Self-monitored blood pressure: a role in clinical practice? Blood Press Monit 2002, 7(1):41-44.) A Bland Altman plot
relating the average of two separate BP readings, taken 2 weeks apart (x-axis), against the difference between those two readings (y-axis) in 85
subjects where there were no treatment changes between readings. Note the mean similarity between the two occasions (blue circle) but the
enormous individual variability.
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tends to be lower that that measured in a surgery or
clinic, although this difference is less if the blood pres-
sure is measured by a nurse rather than by a doctor [5].
2. The reproducibility of the average produced is much
greater than that of clinic measurements (see ref. [2]).
3. Observational data have demonstrated that such
measurements are much better predictors of cardiovas-
cular outcome than any clinic or surgery BP. Arguably,
this is simply because the figure produced by the aver-
age of multiple measurements is a more robust measure
of an individual’s usual pressure.
Ambulatory monitors remain expensive, probably are
best utilised in centres of expertise and, whilst cost-
effective for the diagnosis of hypertension, are not prac-
ticable for the long-term management of individuals
who require changes in drug therapy over months and
years.
Self- or Home Blood Pressure Monitoring
There remains variability in the literature as to what to
call this technology, and although the term ‘home moni-
toring’ is still used extensively, such devices can be used
in any environment.
The science that led to the development of ambula-
tory monitors is available in small, simple-to-use self-
monitors that use the same oscillometric technology
and allow patients to measure blood pressure themselves
semiautomatically as often as they wish or as required.
Home monitors are generally at least an order of magni-
tude cheaper than ambulatory devices and can be bought
without reference to a health care professional in major
pharmacies in the United Kingdom and many other
countries.
As such electronic devices have developed; national
specialist organisations have recommended that they are
validated against the so-called ‘gold standard’ of the mer-
cury manometer and a variety of validation protocols
have been published to ensure that retailed machines are
indeed accurate.
It is salutary to note that there is no obligation on a
manufacturer to demonstrate accuracy before selling their
devices, and there are examples of inaccurate machines
being sold to the public. In Great Britain and Ireland,
there are important agencies that have realised this pro-
blem and maintain a web-based list of validated devices
for both patients and healthcare professionals [6,7].
The average blood pressure obtained by multiple mea-
surements with a self-monitor approximates to the day-
time average of an ambulatory monitor [8], and there are
some who have argued that self-monitoring can displace
an ambulatory monitor in all aspects of hypertension
diagnosis and management. What most home monitors
will still not do is measure blood pressure through the
night, and it is worth mentioning in passing that there
is evidence that nocturnal pressure has independent pre-
dictability in terms of cardiovascular outcomes. As we do
not yet have any clinical strategies as to how to treat noc-
turnal pressure, this remains an area for further research
rather than a practical clinical reality.
Who uses self-monitors?
This is different in different parts of the world, and
there are data to suggest that some 85% of patients with
hypertension in Japan will have purchased a machine.
T h ef i g u r ei sa r o u n d6 5 %i nt h eU S A[ 9 ]b u tp r o b a b l y
as low as 10-30% in the United Kingdom [10]. Most
machines are bought by patients without instruction or
guidance from a healthcare professional, and we have
little information as to how they are used to either help
or hinder the management of individual patients, parti-
cularly within the United Kingdom.
Anecdotally, it is clear that patients will look at the
wide range of blood pressures and learn very quickly that
blood pressure does not stay the same. If they are not
properly educated, they can assume that the machines
are inaccurate, and certainly they receive no consistent
response when they attend the general practitioner, who
may record a much higher blood pressure in the clinic.
Management with self-monitored readings
Most international hypertension guidelines suggest the use
of clinic measurements to guide management and make
little mention of the variability of blood pressure outlined
above. Where they mention the use of ambulatory or self-
blood pressure monitoring, they are careful to emphasise
the importance of using such information in conjunction
with that obtained by clinic measurements, although how
this is to be done is often not defined.
As long as we hold to a definition of 140/90 as the
threshold for defining hypertension, it is worth empha-
sising that for both an average daytime ambulatory pres-
sure and the average of a set of home-monitored
readings, this equates roughly to around 135/85.
There are a number of algorithms and guidelines
available as to how one might use self-monitoring of
blood pressure to diagnose and manage hypertension,
and they all depend upon obtaining a set of readings
before making a clinical decision. Once one averages
20-25 readings, the figure derived is at least twice as
reproducible as that in the clinic and is practicable for
most patients [11] (see Figure 2).
Cautions
N o te v e r yp a t i e n tw i l lb e n e f i tf r o mt h eu s eo fs e l f -
monitors. Whilst newer monitors can detect abnormal
rhythms and indicate that there is such a clinical situa-
tion, their accuracy is questionable in this context. It
Padfield BMC Medicine 2010, 8:55
http://www.biomedcentral.com/1741-7015/8/55
Page 3 of 5should be noted, however, that it is difficult to mea-
sure blood pressure accurately by any methodology in
someone with atrial fibrillation, particularly if there is a
fast ventricular response, but it is probably not suitable
to use electronic, oscillometric devices in the presence
of significant cardiac arrhythmias.
It is often cited that patients may be disturbed by
measuring their own blood pressure and may become
introverted and obsessed by the readings. We have little
idea as to what proportion of the patient population
might suffer in this way, but any guideline to patients
w o u l dn e e dt ot a k et h i si n t oa c c o u n ta n dc o n s i d e rt h e
impact it would have on them as individuals.
There is a natural temptation for patients to measure
their blood pressure at times of stress or during any
unexpected event, and it is important to emphasise to
them that blood pressure will rise under such circum-
stances but that that should not be considered a problem
and should not normally require a change in therapy. It
is the average of many measurements rather than the
single odd reading that should govern the introduction
or a change in drug therapy.
Evidence for benefit
Many of the early trials testing whether the use of self-
monitoring improved blood pressure control in patients
were too small to truly answer the question, and while
some were positive, others showed no evidence of bene-
fit. A meta-analysis by Cappuccio some years ago showed
that there was evidence of a small but significant
improvement in blood pressure control for those patients
who were given a self-monitor [12].
If giving a self-monitor is accompanied by input from
a healthcare professional such that treatment is affected
by the readings obtained more directly, then the evi-
dence of benefit is much more clear-cut [13,14], and
there are several trials underway examining the potential
for longer-term blood pressure control using this simple
methodology.
Within our own group, we are researching the value
of telemetry such that patients are given a self-monitor
with blood pressure readings instantly transmitted wire-
lessly to nurses in a healthcare centre who, on the basis
of a ‘rolling average’, will guide treatment along prede-
termined algorithms of care. A recently published trial
has shown positive results [15].
The term ‘patient empowerment’ is used a lot in modern
healthcare literature, and governments are also keen on
patients taking responsibility themselves for some of the
management of chronic conditions. Hypertension is a clas-
sic case in point because it is not an illness, simply a risk
factor, and generally speaking treatment changes are based
on the figures obtained rather than on any symptoms.
If patients can understand their blood pressure more, see
their own measurements, and see the impact of treatment,
t h e na r g u a b l yt h e ym a yb em o r el i k e l yt oc o m p l yw i t h
medical therapy in the longer term, even if the treatment
does not appear to be making them feel better.
The evidence for this is scarce currently, and again
trials are underway to assess whether this is a reality.
Whether one is a convert to the use of self-blood pres-
sure monitoring or not, it is difficult to argue against the
fact that such machines are being used extensively by
patients themselves in primary care. We can choose to
ignore the results that they obtain or we can work with
them to improve the information about blood pressure
levels and thus perhaps produce more effective drug
treatment for the condition of hypertension that is the
cause of so much morbidity and mortality.
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To establish whether a patient with high (>140/90 
mmHg) office blood pressure is hypertensive complete 
self monitoring protocol* self monitoring protocol
If self monitored blood pressure is
>135/80 mm Hg calculate overall 
cardiovascular risk** and consider treatment
After starting drug treatment, or after any change in 
treatment, repeat self monitoring protocol after 4-6 
cardiovascular risk** and consider treatment
weeks (6 weeks for diuretics)
When self monitored blood pressure is
at target (usually <135/85 mmHg) monitor
If blood pressure is in the target range, repeat self 
at target (usually <135/85 mmHg) monitor
at intervals (see below)
monitoring protocol at intervals of 9-12 months (earlier if 
clinical circumstances change) 
Figure 2 Suggested model for self-monitoring of blood
pressure, adapted from [11] (BMJ Publishing Group Ltd.
Copyright 2008) Whilst there is no clear evidence base to
prefer this model, it will deliver an average of 24 readings and
has been adopted by the European Society of Hypertension
[17], the American Society of Hypertension and the American
College of Cardiology (see [9]). *The protocol should consist of a
series of measurements over 7 days with two measurements
morning and evening. The first day’s data should be discarded and
the remaining 24 measurements averaged. Any management
decision must be preceded by monitoring, such that at least 10
measurements are available for averaging. **Cardiovascular risk is
calculated using equations that incorporate office blood pressure
measurements, not self-monitored readings.
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